Proje Geliştirme ve
Koordinasyon Birimi

2016-03-11 Spain: Zika virus-SC1-PM-XX–2016


 

Zika virus-SC1-PM-XX–2016

Description of the project offered: 
We are a biotechnology company specialized in research and development of new immunological treatments for application in human and animal health to treat and prevent infectious, inflammatory and autoimmune diseases. We have strategic partners in the public sector, headed by the Center for Molecular Biology Severo Ochoa (CBMSO) of Madrid, and highly prestigious private and pharmaceutical companies. 
Zika virus fast spread along Latin America and the South Pacific and its relationship with severe congenital malformations and autoimmune diseases justify the need for further research into the mechanism of action of the virus, its diagnosis and prevention (i.e. vaccine and vector control) as well as its potential association with microcephaly and neurological complications. If causality were demonstrated, finding biomarkers to predict the risk of neurological damage and malformations would be key. A capacity for Zika and other flaviviruses to infect and kill neural cells have been demonstrated. Multiple pattern recognition receptors (PRR) are clearly involved in the initiation of the antiviral response to most flaviviruses. Prior studies in West Nile Virus suggest that the inflammatory response produced by the recognition of the virus by PRR resulted in increased blood-brain barrier permeability and enhance the virulence
We aim to investigate the role of PRR and the resulting inflammatory response in the pathogenicity of the virus and whether differences in the maturity of the immune system correlate with different disease severity. If our hypothesis is correct, modulation of the inflammatory response could represent a potential treatment. We already count with a Partner in Colombia with access to numerous samples from Zika patients, a diagnostics company aiming to develop a diagnostic kit, a Hospital involved in genomic studies and a partner to develop serological assays.
Any complementary research proposal will be welcome or we could consider joining an existing consortium.
Project proposer:   Beatriz Salvador ()
Partner role:  Project coordinator 
Partner organisation:  Small or medium-sized enterprise (SME)
Call for proposal title:  Personalised Medicine 
Call for proposal identifier:  H2020-SC1-2016-2017


Description of the collaboration sought: 
Any complementary research proposal will be welcome or we could consider joining an existing consortium. 
Expertise sought: Scientific research, Coordination. Cooperation, Innovation. Technology transfer, Legislation. Regulations, Policies, Information. Media, Project management methodologies, Veterinary and animal sciences, Medical biotechnology, Life sciences, Biotechnology, Medicine. Health, Industrial biotech, ICT Applications, Information processing. Information systems, 
Roles sought: Project participant, Project coordinator, 
Organisation types sought: Industry, Technology transfer, Small or medium-sized enterprise (SME), Research, Non-governmental organisation (NGO), Education, 
Countries sought: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Albania, Bosnia and Herzegovina, Croatia, Iceland, Israel, Liechtenstein, Macedonia, the former Yugoslav Republic of, Montenegro, Norway, Serbia, Switzerland, Turkey, 

Call for proposal specific information
The referenced call for proposals has no specific fields defined.